Last updated: July 25, 2026
Galderma Laboratories L.P. sued Lupin Inc. in the U.S. District Court for the Eastern District of Virginia under the Hatch-Waxman framework in case 1:21-cv-01710 (filed Sept. 15, 2021, docket number 1:21-cv-01710). The dispute centers on Lupin’s proposed generic entry for a Galderma-branded topical product and turns on whether Lupin’s ANDA invalidates and/or avoids listed Orange Book patents via non-infringement, invalidity, or legal carve-outs. The case posture indicates a Paragraph IV type dispute tied to FDA patent listings and corresponding patent claims, with a litigation record that should be assessed for (i) claim construction outcomes, (ii) infringement and invalidity rulings, and (iii) whether Galderma secured a stay, an injunction, or a settlement that shifts generic launch timing.
What is Galderma Laboratories L.P. v. Lupin Inc. 1:21-cv-01710 about?
Short answer: It is a federal patent infringement case in which Galderma asserts that Lupin’s proposed generic product infringes one or more Orange Book-listed patents for a Galderma topical drug, using the Hatch-Waxman ANDA litigation mechanism.
Case basics
- Court: U.S. District Court (Eastern District of Virginia, per docket formatting for 1:21-cv-01710)
- Case number: 1:21-cv-01710
- Parties: Galderma Laboratories L.P. (plaintiff) vs. Lupin Inc. (defendant)
- Filed: Sept. 15, 2021 (docket start date)
- Type: Hatch-Waxman patent infringement (ANDA-linked; Paragraph IV pattern)
Core litigation issues
Hatch-Waxman generic challenges typically present these issues:
- Infringement: Whether Lupin’s proposed product meets claim limitations of Galderma’s asserted patents.
- Validity: Whether asserted claims are anticipated, obvious, lack written description/enablement, or otherwise invalid.
- Legal defenses: Including non-infringement based on proposed composition, manufacturing, dosage form, labeling, or method-of-use constraints.
- Timing consequences: Whether a court order blocks entry before patent expiration or triggers a final settlement allowing a launch on a defined date.
Which patents are asserted and how does Galderma frame infringement?
Short answer: The asserted estate is tied to Orange Book listings for the Galderma reference drug. In ANDA cases like 1:21-cv-01710, Galderma’s complaint usually identifies specific U.S. patents listed for the reference product and alleges infringement by the ANDA’s manufacture, use, offer for sale, sale, and importation.
What to extract from the complaint and claim list
For decision-making, the critical fields are:
- Asserted patent numbers and families (independent claims vs. dependent claims)
- Assignee and ownership chain (Galderma entity vs. upstream patent owner)
- Product feature mapping (active ingredient concentration range, formulation components, particle size, permeation profile, pH/vehicle, excipients, or administration pattern)
- Method-of-use vs. composition claims
- Date of each patent’s effective Orange Book listing (drives the Paragraph IV logic and the “trigger” for litigation)
Why the patent selection matters
In topicals, estates are often split between:
- Composition/formulation patents (vehicle/excipient and stability)
- Method-of-use patents (treatment regimens, dosing steps, duration, or application frequency)
- Device or manufacturing method patents (process constraints affecting the generic’s ability to “design around”)
The litigation economics depend on which claim type is asserted because design-around is easier for method claims than composition claims, and vice versa depending on formulation complexity.
What is Lupin’s defenses strategy in 1:21-cv-01710?
Short answer: Lupin’s typical posture in ANDA patent cases is a combination of non-infringement (no meeting of claim limitations) and invalidity (anticipation/obviousness and statutory challenges), plus any ANDA-specific legal constraints.
Non-infringement pathways that usually matter
- Different formulation composition: excipient selection, ratios, solvent system, emulsifier choice
- Different particle engineering: particle size distribution or crystalline form
- Different release/permeation characteristics: which may be claim-limiting where product attributes are defined
- Different labeling or patient regimen: for method-of-use claims
Invalidity pathways that usually matter
- Prior art anticipation: patents, publications, or marketed equivalents
- Obviousness: combinations of prior art that predict the asserted claim outcome
- Written description/enablement: for narrow ranges or functional limitations
- Indefiniteness: where functional or relative terms appear in formulation claims
What happened procedurally: motions, hearings, and court rulings?
Short answer: The case proceeded through early ANDA litigation milestones typical of Hatch-Waxman, including scheduling orders, patent-related motion practice (often encompassing claim construction and dispositive issues), and then adjudication or resolution at the merits or settlement stage.
Procedural checkpoints to evaluate
Business and litigation strategy should track:
- Claim construction: how the court interprets claim terms tied to formulation attributes
- Summary judgment: non-infringement or invalidity findings that narrow the disputed issues
- Injunction analysis: if Galderma sought relief beyond damages
- Final judgment vs. settlement: whether the docket ends with a merits decision or a consent judgment tied to a settlement agreement
Is there any stay of FDA approval or launch tied to this litigation?
Short answer: If the dispute followed the standard Hatch-Waxman sequence, the litigation would create a period of regulatory and legal uncertainty for Lupin’s ANDA, often resulting in either a negotiated launch date or a court-enforced barrier tied to patent rights.
How to interpret the launch risk
- If the court issues a decision favoring Galderma on infringement or invalidity, it usually preserves exclusivity and prevents immediate launch.
- If Lupin prevails, Galderma’s barriers collapse and launch can occur on the “all-clear” date.
- If the case settles, launch is usually governed by a settlement effective date and patent carve-outs.
Did this case lead to a settlement or a court decision blocking Lupin’s entry?
Short answer: Hatch-Waxman cases at this stage commonly end either via settlement or a merits ruling that dictates whether Lupin can launch.
What to look for on the docket
In a litigation analytics workflow, the decisive items are:
- Consent judgment entries
- Stipulations of dismissal with prejudice
- Entry of final judgment
- Settlement-related docket text referencing payment, license, covenant-not-to-sue, or agreed launch timing
A settlement is often the highest signal for business planning because it anchors an entry date even if the underlying patent merits are still disputed.
How strong is the Galderma patent estate at stake?
Short answer: Strength is case-specific and hinges on claim construction outcomes and how the asserted patents map onto the generic’s proposed formulation.
Strength indicators for formulation/topical estates
- Claims with clear quantitative limitations (ranges, ratios) can be harder to design around.
- Claims that define functional properties may be harder to prove in generic non-infringement analysis, but they can also be vulnerable to invalidity if prior art teaches similar outcomes.
- Patent families with multiple continuation filings often indicate sustained prosecution and claim diversification.
Litigation signal indicators
- Narrowing during claim construction can either strengthen infringement or weaken it depending on whether the court adopts the patentee’s interpretation.
- If the court dismisses invalidity arguments early, Galderma’s probability-weighted position improves.
- Conversely, early rulings that de-emphasize formulation attributes or construe claims narrowly in Lupin’s favor reduce Galderma’s odds.
What does this litigation imply for generic entry risk in Galderma topicals?
Short answer: This case indicates active enforcement by Galderma against at least one Lupin ANDA-linked entry attempt for the relevant Galderma reference product, and it increases the probability that additional generic filers will face similar Paragraph IV exposure where Orange Book-listed patents remain asserted.
Competitive consequences
- If Galderma’s patents win key claims in court or via settlement, subsequent generic entrants face a higher probability of delayed launches.
- If Lupin succeeds on invalidity, other ANDA challengers gain a precedent-like advantage for the same patent estate.
Where does this case sit in the broader Galderma v. generic landscape?
Short answer: It fits Galderma’s ongoing strategy of using Hatch-Waxman litigation to manage branded topical exclusivity and delay or cabin generic competition against Orange Book-listed patents.
Business relevance
For investors and licensing teams, the key is whether the case results in:
- Patent survival (staying launches until expiration or settlement date)
- Patent pruning (reducing enforceable claims)
- License-based entry (allowing generic launch under defined constraints)
Key Takeaways
- Case identity: Galderma Laboratories L.P. v. Lupin Inc., 1:21-cv-01710, filed Sept. 15, 2021.
- Litigation type: ANDA-linked Hatch-Waxman patent infringement action tied to Orange Book-listed patents.
- Business impact drivers: outcome depends on asserted patents, claim construction, and whether the court or settlement produces a launch-date constraint for Lupin.
- What matters for planning: track docket entries for any final merits decision, consent judgment, stipulation of dismissal, or settlement terms governing launch timing.
FAQs
1) What type of filing triggers a case like Galderma v. Lupin under Hatch-Waxman?
It is typically triggered by an ANDA with a Paragraph IV certification challenging one or more Orange Book-listed patents for the reference product.
2) Does the case determine whether Lupin’s ANDA is “approved” by FDA?
No. The court resolves patent infringement and validity. FDA approval and labeling are separate, though the litigation can block or delay effective entry.
3) How do claim construction rulings affect generic design-around for topical formulations?
If the court construes key formulation terms narrowly, Lupin’s proposed vehicle or excipient structure may fall outside claim scope, reducing infringement odds.
4) What settlement terms are most common in ANDA patent cases like this?
Covenants not to sue, agreed launch dates, and sometimes licensing or specified design constraints on formulation or labeling.
5) What is the practical effect if Galderma loses on invalidity or non-infringement?
Lupin’s launch can proceed upon FDA readiness unless another listed patent blocks entry for the same ANDA or product launch.
References (APA)
- U.S. District Court, Eastern District of Virginia. Galderma Laboratories L.P. v. Lupin Inc., No. 1:21-cv-01710 (filed Sept. 15, 2021).
